Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up

The objective of this paper is to examine the effects of Imatinib on patients who are at the chronic phase of chronic myeloid leukemia (CML). Method: Totally, 79 patients with CML who received the treatment between 2003 and 2020 entered the study. The patients were evaluated in terms of molecular re...

Descripción completa

Detalles Bibliográficos
Autores principales: Aznab, Mozafar, Shahriari-Ahmadi, Ali, Heydarpour, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487986/
https://www.ncbi.nlm.nih.gov/pubmed/34631408
http://dx.doi.org/10.1016/j.lrr.2021.100271
_version_ 1784578059407458304
author Aznab, Mozafar
Shahriari-Ahmadi, Ali
Heydarpour, Fatemeh
author_facet Aznab, Mozafar
Shahriari-Ahmadi, Ali
Heydarpour, Fatemeh
author_sort Aznab, Mozafar
collection PubMed
description The objective of this paper is to examine the effects of Imatinib on patients who are at the chronic phase of chronic myeloid leukemia (CML). Method: Totally, 79 patients with CML who received the treatment between 2003 and 2020 entered the study. The patients were evaluated in terms of molecular response rate and overall survival (OS). Results: About 75.9% of patients achieved deep molecular response in mean follow-up of 89.92 months. The OS rate was about 91.2%. Conclusion: There was no considerable cumulative toxicity with Imatinib long-term use. A high percent of patients had a deep molecular response.
format Online
Article
Text
id pubmed-8487986
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84879862021-10-08 Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up Aznab, Mozafar Shahriari-Ahmadi, Ali Heydarpour, Fatemeh Leuk Res Rep Article The objective of this paper is to examine the effects of Imatinib on patients who are at the chronic phase of chronic myeloid leukemia (CML). Method: Totally, 79 patients with CML who received the treatment between 2003 and 2020 entered the study. The patients were evaluated in terms of molecular response rate and overall survival (OS). Results: About 75.9% of patients achieved deep molecular response in mean follow-up of 89.92 months. The OS rate was about 91.2%. Conclusion: There was no considerable cumulative toxicity with Imatinib long-term use. A high percent of patients had a deep molecular response. Elsevier 2021-09-24 /pmc/articles/PMC8487986/ /pubmed/34631408 http://dx.doi.org/10.1016/j.lrr.2021.100271 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Aznab, Mozafar
Shahriari-Ahmadi, Ali
Heydarpour, Fatemeh
Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
title Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
title_full Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
title_fullStr Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
title_full_unstemmed Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
title_short Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
title_sort evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487986/
https://www.ncbi.nlm.nih.gov/pubmed/34631408
http://dx.doi.org/10.1016/j.lrr.2021.100271
work_keys_str_mv AT aznabmozafar evaluationoftheoutcomesinpatientswithchronicmyeloidleukemiatreatedwithimatinibin18yearfollowup
AT shahriariahmadiali evaluationoftheoutcomesinpatientswithchronicmyeloidleukemiatreatedwithimatinibin18yearfollowup
AT heydarpourfatemeh evaluationoftheoutcomesinpatientswithchronicmyeloidleukemiatreatedwithimatinibin18yearfollowup

Ejemplares similares